|
Revenue - Additional Information (Detail)
|
3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 1 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jun. 30, 2014
USD ($)
|
Jun. 30, 2013
USD ($)
|
Jun. 30, 2014
USD ($)
|
Jun. 30, 2014
RUB
|
Jun. 30, 2013
USD ($)
|
Jun. 30, 2013
RUB
|
Dec. 31, 2013
Amgen, Inc. [Member]
|
Jan. 31, 2013
Amgen, Inc. [Member]
USD ($)
|
Jun. 30, 2014
Amgen, Inc. [Member]
USD ($)
|
Jun. 30, 2013
Amgen, Inc. [Member]
USD ($)
|
Jun. 30, 2014
Amgen, Inc. [Member]
USD ($)
|
Jun. 30, 2013
Amgen, Inc. [Member]
USD ($)
|
Mar. 31, 2013
Pfizer Inc. [Member]
USD ($)
Option
|
Jun. 30, 2014
Pfizer Inc. [Member]
USD ($)
|
Jun. 30, 2013
Pfizer Inc. [Member]
USD ($)
|
Jun. 30, 2014
Pfizer Inc. [Member]
USD ($)
|
Jun. 30, 2013
Pfizer Inc. [Member]
USD ($)
|
Apr. 30, 2013
AstraZeneca AB [Member]
USD ($)
|
Jun. 30, 2014
AstraZeneca AB [Member]
USD ($)
|
Jun. 30, 2013
AstraZeneca AB [Member]
USD ($)
|
Jun. 30, 2014
AstraZeneca AB [Member]
USD ($)
|
Jun. 30, 2013
AstraZeneca AB [Member]
USD ($)
|
Jun. 30, 2014
F. Hoffmann-La Roche Ltd [Member]
USD ($)
|
Jun. 30, 2014
F. Hoffmann-La Roche Ltd [Member]
USD ($)
|
Jun. 30, 2014
Russia [Member]
Ministry of Industry and Trade of Russian Federation [Member]
USD ($)
|
Jun. 30, 2013
Russia [Member]
Ministry of Industry and Trade of Russian Federation [Member]
USD ($)
|
Jun. 30, 2014
Russia [Member]
Ministry of Industry and Trade of Russian Federation [Member]
USD ($)
|
Jun. 30, 2013
Russia [Member]
Ministry of Industry and Trade of Russian Federation [Member]
USD ($)
|
|
| Revenues [Line Items] | ||||||||||||||||||||||||||||
| Total revenue | $ 300,000 | 12,000,000 | $ 400,000 | 11,700,000 | ||||||||||||||||||||||||
| Contract amount recognized | 253,000 | 365,000 | 418,000 | 365,000 | 253,000 | 365,000 | 418,000 | 365,000 | ||||||||||||||||||||
| Company received upfront payment | 5,000,000 | 800,000 | 4,000,000 | 4,000,000 | ||||||||||||||||||||||||
| Option exercise period | 6 months | 30 months | ||||||||||||||||||||||||||
| Reduction in net loss per share, basic and diluted | $ 0.05 | |||||||||||||||||||||||||||
| Company recognized amount related to the research, option and license agreement | 807,000 | 918,000 | 819,000 | 2,300,000 | 26,000 | 673,000 | 87,000 | 673,000 | 1,400,000 | 564,000 | 2,700,000 | 564,000 | 0 | 0 | ||||||||||||||
| Company granted option | 2 | |||||||||||||||||||||||||||
| Total contingent payments | 89,500,000 | 193,000,000 | ||||||||||||||||||||||||||
| Additional contingent payments | $ 110,000,000 | |||||||||||||||||||||||||||